Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer	Platinum-sensitive Recurrent Ovarian Cancer	Not yet recruiting	Phase 3	2026-09-16		NCT07821606

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Hansoh BioMedical R&D Company	37

39 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anhui Provincial Hospital	Hefei	China	32
Anyang Cancer Hospital	Anyang	China	7
Chongqing University Cancer Hospital	Chongqing	China	54
Fudan University Shanghai Cancer Center	Shanghai	China	257
Guangxi Medical University Cancer Hospital	Nanning	China	24
Harbin Medical University Cancer Hospital	Harbin	China	102
Hubei Cancer Hospital	Wuhan	China	95
Hunan Cancer Hospital	Changsha	China	123
Jiangsu Cancer Hospital	Nanjing	China	19
Jiangsu Province Hospital	Nanjing	China	89
Jiangxi Cancer Hospital	Nanchang	China	48
Jiangxi Maternal and Child Health Hospital	Nanchang	China	5
Liaoning Cancer Hospital	Shenyang	China	15
Linyi People's Hospital	Linyi	China	10
National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences	Beijing	China	1
Peking Union Medical College Hospital	Beijing	China	201
Peking University Cancer Hospital	Beijing	China	32
Qilu Hospital of Shandong University	Jinan	China	138
Shandong Cancer Hospital	Jinan	China	1
Shanxi Cancer Hospital	Taiyuan	China	1
Shengjing Hospital Of China Medical University	Shenyang	China	54
Sun Yat-sen University Cancer Center	Guangzhou	China	315
The Affiliated Hospital of Southwest Medical University	Luzhou	China	18
The First Affiliated Hospital of Chongqing Medical University	Chongqing	China	70
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	China	10

Clinical trials